Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 250,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total value of $10,515,000.00. Following the transaction, the chief executive officer directly owned 200,000 shares in the company, valued at approximately $8,412,000. This represents a 55.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

TEM stock opened at $44.29 on Friday. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The firm has a market cap of $7.95 billion, a P/E ratio of -25.75 and a beta of 3.46. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $104.32. The stock’s 50 day simple moving average is $51.45 and its 200 day simple moving average is $52.77.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same period last year, the business posted ($0.22) earnings per share. The firm’s revenue for the quarter was up 21.6% on a year-over-year basis. As a group, equities research analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current year.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q2 results exceeded expectations. Tempus reported an adjusted loss of $0.04 per share, substantially narrower than the $0.14 analyst estimate and improved from a $0.22 loss a year earlier. Revenue rose 21.6% year over year to $382.49 million, slightly above the $379.69 million consensus. Tempus AI Q2 earnings report
• Positive Sentiment: Core diagnostics growth and AI investments supported the quarter. Management said investments in artificial intelligence are driving strong growth in the company’s two largest businesses, particularly Oncology Diagnostics. The company also cited progress in data and modeling capabilities, supporting its precision-medicine strategy. Tempus Reports Second Quarter 2026 Results
• Positive Sentiment: Full-year revenue guidance remained solid. Tempus maintained or updated 2026 revenue guidance at approximately $1.6 billion, broadly in line with Wall Street expectations. The guidance reinforces investor confidence in continued top-line expansion, although it does not represent a major upside surprise. Tempus AI earnings conference call

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TEM shares. Jefferies Financial Group started coverage on shares of Tempus AI in a research note on Monday, April 13th. They set an “underperform” rating and a $35.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. BTIG Research reaffirmed a “buy” rating and set a $80.00 target price on shares of Tempus AI in a report on Monday, June 1st. Freedom Capital upgraded Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Finally, HC Wainwright reissued a “buy” rating on shares of Tempus AI in a report on Friday, July 24th. Nine equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $68.92.

Institutional Trading of Tempus AI

Large investors have recently modified their holdings of the company. Aberdeen Group plc boosted its stake in Tempus AI by 64.2% during the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after purchasing an additional 102,878 shares during the period. Pictet Asset Management Holding SA increased its stake in shares of Tempus AI by 291.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after purchasing an additional 36,096 shares during the period. Bogart Wealth LLC raised its holdings in shares of Tempus AI by 365,087.5% during the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after buying an additional 58,414 shares during the last quarter. Eagle Health Investments LP bought a new stake in shares of Tempus AI during the first quarter valued at approximately $11,588,000. Finally, Alethea Capital Management LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at approximately $1,863,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.